Hong Kong · Delayed Price · Currency is HKD Mabpharm Statistics
Total Valuation
Mabpharm has a market cap or net worth of HKD 2.08 billion. The enterprise value is 2.33 billion.
| Market Cap | 2.08B |
| Enterprise Value | 2.33B |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mabpharm has 4.12 billion shares outstanding.
| Current Share Class | 4.12B |
| Shares Outstanding | 4.12B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 49.95% |
| Owned by Institutions (%) | n/a |
| Float | 941.30M |
Valuation Ratios
The trailing PE ratio is 22.67.
| PE Ratio | 22.67 |
| Forward PE | n/a |
| PS Ratio | 2.34 |
| PB Ratio | 9.31 |
| P/TBV Ratio | 9.31 |
| P/FCF Ratio | 21.55 |
| P/OCF Ratio | 17.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.10, with an EV/FCF ratio of 24.12.
| EV / Earnings | 23.59 |
| EV / Sales | 2.62 |
| EV / EBITDA | 21.10 |
| EV / EBIT | 56.30 |
| EV / FCF | 24.12 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 1.59.
| Current Ratio | 0.84 |
| Quick Ratio | 0.49 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | 3.23 |
| Debt / FCF | 3.69 |
| Interest Coverage | 3.35 |
Financial Efficiency
Return on equity (ROE) is 58.49% and return on invested capital (ROIC) is 4.95%.
| Return on Equity (ROE) | 58.49% |
| Return on Assets (ROA) | 2.00% |
| Return on Invested Capital (ROIC) | 4.95% |
| Return on Capital Employed (ROCE) | 5.39% |
| Weighted Average Cost of Capital (WACC) | 6.85% |
| Revenue Per Employee | 2.26M |
| Profits Per Employee | 250,805 |
| Employee Count | 394 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 0.52 |
Taxes
| Income Tax | -61.16M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.13% in the last 52 weeks. The beta is 0.60, so Mabpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -23.13% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.46 |
| Relative Strength Index (RSI) | 60.83 |
| Average Volume (20 Days) | 37,800 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mabpharm had revenue of HKD 888.77 million and earned 98.82 million in profits. Earnings per share was 0.02.
| Revenue | 888.77M |
| Gross Profit | 801.16M |
| Operating Income | 41.41M |
| Pretax Income | 37.66M |
| Net Income | 98.82M |
| EBITDA | 104.04M |
| EBIT | 41.41M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 107.74 million in cash and 356.39 million in debt, with a net cash position of -248.65 million or -0.06 per share.
| Cash & Cash Equivalents | 107.74M |
| Total Debt | 356.39M |
| Net Cash | -248.65M |
| Net Cash Per Share | -0.06 |
| Equity (Book Value) | 223.78M |
| Book Value Per Share | 0.05 |
| Working Capital | -94.43M |
Cash Flow
In the last 12 months, operating cash flow was 118.69 million and capital expenditures -22.05 million, giving a free cash flow of 96.64 million.
| Operating Cash Flow | 118.69M |
| Capital Expenditures | -22.05M |
| Depreciation & Amortization | 63.62M |
| Net Borrowing | -2.76M |
| Free Cash Flow | 96.64M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 90.14%, with operating and profit margins of 4.66% and 11.12%.
| Gross Margin | 90.14% |
| Operating Margin | 4.66% |
| Pretax Margin | 4.24% |
| Profit Margin | 11.12% |
| EBITDA Margin | 11.71% |
| EBIT Margin | 4.66% |
| FCF Margin | 10.70% |
Dividends & Yields
Mabpharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 4.74% |
| FCF Yield | 4.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mabpharm has an Altman Z-Score of 0.39 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.39 |
| Piotroski F-Score | 7 |